Delcath’s Melblez Chemosaturation System To Face ODAC Scrutiny

FDA’s Oncologic Drugs Advisory Committee will review the drug/device combination for treatment of patients with unresectable ocular melanoma that is metastatic to the liver. The system, which uses the chemotherapy drug melphalan, has shown significant improvement in hepatic progression-free survival.

FDA’s Oncologic Drugs Advisory Committee on May 2 will consider approval of Delcath Systems Inc.’s chemosaturation system Melblez Kit for a narrower indication than originally requested by the company, in part due to advances in the treatment of melanoma.

ODAC will discuss the use of Melblez Kit (Melblez (melphalan) injection for use with the Delcath Hepatic Delivery System), a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America